3.9 Review

Earlier diagnosis and earlier treatment of COPD in primary care

期刊

PRIMARY CARE RESPIRATORY JOURNAL
卷 20, 期 1, 页码 15-22

出版社

PRIMARY CARE RESPIRATORY SOC-PCRS UK
DOI: 10.4104/pcrj.2010.00060

关键词

COPD; early diagnosis; early treatment; primary care

资金

  1. UK National Health Service
  2. Aerocrine
  3. AstraZeneca
  4. Boehringer Ingelheim
  5. GlaxoSmithKline
  6. Merck
  7. Sharpe
  8. Dohme
  9. Novartis
  10. Pfizer
  11. Schering Plough
  12. Teva
  13. Nycomed

向作者/读者索取更多资源

Chronic obstructive pulmonary disease (COPD) is a progressive disease that begins many years before a diagnosis is usually made. The need for an early and confirmed diagnosis of COPD is increasingly appreciated by primary care physicians in whose hands the ability to make improvements in early diagnosis largely rests. Case-finding of patients with symptoms of lifestyle limitation is probably the most practical way to achieve early diagnosis. Evidence suggests a burden of early COPD on afflicted people and their families. Early encouragement of smoking cessation, in conjunction with management of symptoms and treating activity limitation and exacerbations by appropriate non-pharmacologic and pharmacologic management at the earliest possible stage, could positively affect the impact and progression of the disease. (C) 2011 Primary Care Respiratory Society UK. All rights reserved. Q Zhang et al. Prim Care Respir J 2011; 20(1): 97-101 doi:10.4104/pcrj.2010.00061

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据